TY1A-DR6 Antibody

What is DR6 and why is it a significant target for antibody-based research?

DR6 (Death Receptor 6), also known as TNFRSF21 (Tumor necrosis factor receptor superfamily member 21) and CD358, is a type I transmembrane protein in the TNF receptor superfamily that plays crucial roles in promoting apoptosis through pathways involving NF-kappa-B activation, BAX-mediated mechanisms, and cytochrome c release from mitochondria into the cytoplasm. It functions prominently in neuronal apoptosis, particularly in response to amyloid peptides derived from APP (amyloid precursor protein), and is required for both normal cell body death and axonal pruning in neural development . DR6 is expressed on multiple cell types including monocytes, resting CD4+ T cells, pro-, pre-, and naïve B cells, as well as certain prostate cancer cells, making it a valuable research target for studying various physiological and pathological processes . The antibody-based research on DR6 enables scientists to investigate its involvement in both immune regulation and neurodegeneration pathways, providing insights into potential therapeutic interventions for conditions such as autoimmune diseases, neurodegenerative disorders, and certain cancers .

How should researchers determine which DR6 antibody format is most suitable for their experimental design?

Researchers should base their selection of DR6 antibody format on several critical experimental parameters including the intended application, target species, and specific research question being addressed. For protein detection applications such as Western blot (WB), both monoclonal and polyclonal antibodies can be effective, with polyclonal antibodies often providing greater sensitivity due to their recognition of multiple epitopes, while monoclonal antibodies offer higher specificity to a single epitope . When designing experiments requiring high specificity such as mechanistic studies or targeted inhibition, researchers should prioritize monoclonal antibodies like recombinant human monoclonal antibodies which provide consistent lot-to-lot reproducibility and defined epitope recognition . For more complex applications such as in vivo studies or functional assays, specially designed antibodies (like the low endotoxin, azide-free varieties) are essential to avoid experimental artifacts and ensure biological relevance . Additionally, researchers must carefully verify the species reactivity of their selected antibody—some DR6 antibodies react with human samples only, while others demonstrate cross-reactivity with mouse and rat samples—which is critical for translational research between animal models and human applications .

What are the primary applications for DR6 antibodies in neuroscience research?

DR6 antibodies serve as essential tools in neuroscience research for investigating neuronal apoptosis mechanisms, particularly in the context of neurodegenerative diseases where DR6 plays a significant role in response to amyloid peptides derived from APP. These antibodies enable researchers to study the trophic-factor deprivation processes that trigger the cleavage of surface APP by beta-secretase to release sAPP-beta, which is further processed to release an N-terminal fragment (N-APP) that binds to DR6 . Through immunohistochemistry (IHC) and immunofluorescence techniques, researchers can visualize DR6 expression patterns in neural tissues and investigate its co-localization with other proteins involved in neurodegeneration pathways . Additionally, functional blocking antibodies against DR6 can be employed in experimental models to determine the consequences of DR6 inhibition on axonal pruning, neuronal cell body death, and potential neuroprotective effects in pathological conditions . DR6 antibodies also facilitate the study of the receptor's role in negatively regulating oligodendrocyte survival, maturation, and myelination—processes crucial to understanding demyelinating disorders and potential remyelination strategies .

What are the optimal protocols for using DR6 antibodies in Western blot applications?

For optimal Western blot results with DR6 antibodies, researchers should begin with careful sample preparation, ensuring complete protein extraction using buffers containing appropriate protease inhibitors to preserve the integrity of DR6, which has a molecular weight of approximately 110 kDa when fully glycosylated . Prior to loading samples, it is crucial to determine the appropriate protein concentration (typically 20-50 μg of total protein per lane) and denature samples completely in Laemmie buffer with reducing agents, as DR6 contains multiple cysteine-rich motifs that form disulfide bonds which must be reduced for proper epitope exposure . During electrophoresis and transfer steps, researchers should optimize parameters for the high molecular weight of DR6, potentially using gradient gels (4-12% or 4-15%) and extended transfer times with methanol-containing buffers to ensure complete transfer of this large membrane-bound protein . For the immunodetection phase, antibody dilutions should be carefully optimized (typically starting with 1:500 to 1:1000 for polyclonal antibodies like those cataloged as A15665, A283887, and A49829) with overnight incubation at 4°C to maximize specific binding while minimizing background signals . To validate findings, researchers should include appropriate positive controls (lysates from cells known to express DR6 such as monocytes or certain prostate cancer cell lines) and negative controls (lysates from DR6-knockout cells or tissues), along with blocking peptides when available to confirm antibody specificity .

How should researchers approach DR6 antibody-based immunohistochemistry experiments?

Successful DR6 antibody-based immunohistochemistry requires meticulous tissue preparation, beginning with appropriate fixation methods—typically 4% paraformaldehyde for frozen sections or formalin for paraffin-embedded tissues—with fixation times optimized to preserve DR6 epitopes while maintaining tissue morphology. For paraffin-embedded specimens, effective antigen retrieval is essential due to DR6's extensive glycosylation and membrane localization, with researchers typically employing heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0), with the specific buffer determined through empirical testing with antibodies such as the Anti-TNFRSF21 Antibody (A44995) specifically validated for IHC applications . When performing the immunostaining procedure, researchers should implement a robust blocking step using serum from the species in which the secondary antibody was raised (typically 5-10% normal serum) supplemented with 0.1-0.3% Triton X-100 for membrane permeabilization to access the transmembrane and intracellular portions of DR6 . For primary antibody incubation, dilutions should be carefully optimized (starting with manufacturer recommendations, typically 1:100 to 1:500 for IHC), with incubation performed overnight at 4°C to maximize specific binding while minimizing background signals . Validation of staining specificity is critically important and should include appropriate positive controls (tissues known to express DR6 such as neural tissues, lymphoid organs, or prostate samples), negative controls (omission of primary antibody and ideally DR6-knockout tissues), and when possible, comparison of staining patterns using multiple DR6 antibodies raised against different epitopes to confirm consistent localization patterns .

What are the key considerations for using DR6 antibodies in flow cytometry experiments?

When implementing DR6 antibodies in flow cytometry experiments, researchers must first ensure they select antibodies specifically validated for this application, such as the Anti-DR6 Research Grade Biosimilar (A324000) which is specifically tested for FACS applications . Cell preparation protocols are critical for preserving surface expression of DR6, requiring gentle dissociation methods (enzyme-free when possible) and maintenance of cells at 4°C in buffers containing sodium azide to prevent receptor internalization or shedding which could dramatically affect detection sensitivity . Appropriate titration of the primary antibody is essential to determine the optimal concentration that maximizes the signal-to-noise ratio, typically beginning with the manufacturer's recommended dilution (1:100 to 1:200) and testing a range above and below this value using positive control cells with confirmed DR6 expression such as monocytes or selected prostate cancer cell lines . For multicolor flow cytometry panels, researchers must carefully consider fluorophore selection to avoid spectral overlap with other markers, particularly when studying immune cell populations where multiple surface receptors may need to be analyzed simultaneously . Validation controls are essential and should include fluorescence-minus-one (FMO) controls, isotype controls matched to the DR6 antibody's isotype (such as IgG2a for the monoclonal Luke-1 clone), and ideally, comparison of staining between wild-type and DR6-knockout cells to definitively establish specificity and appropriate gating strategies .

How can DR6 antibodies be utilized to investigate the interaction between DR6 and amyloid precursor protein fragments in neurodegeneration studies?

Investigating the interaction between DR6 and amyloid precursor protein (APP) fragments requires a multifaceted approach where DR6 antibodies serve as crucial tools for both detection and functional studies. Researchers can employ co-immunoprecipitation techniques using DR6 antibodies to pull down the receptor complex and associated N-APP fragments, followed by western blot analysis to detect and quantify the interaction under various experimental conditions such as trophic factor deprivation that triggers APP cleavage . For visualization of interactions in situ, proximity ligation assays combining DR6 antibodies with antibodies against N-APP fragments can reveal direct molecular interactions at the subcellular level within neurons, providing spatial information about where these interactions occur along axons or at growth cones . Functional blocking studies represent another powerful approach, where antibodies like the low endotoxin, azide-free Anti-DR6 Research Grade Biosimilar (A324000) can be applied to neuronal cultures or injected in vivo to determine if blocking DR6 can prevent N-APP-induced caspase activation (particularly caspase-3 in neuronal cell bodies and caspase-6 in axons) and subsequent neurodegeneration . Additionally, researchers can develop or utilize reporter systems where DR6-expressing cells are engineered to produce quantifiable signals upon binding N-APP fragments, and then test whether pre-incubation with various DR6 antibodies targeting different epitopes can inhibit or modify this interaction, providing insights into the structural basis of DR6-APP recognition .

What methods should researchers employ to study DR6-mediated signaling pathways in immune cell populations?

To comprehensively study DR6-mediated signaling pathways in immune cells, researchers should first employ flow cytometry with DR6 antibodies such as the Anti-DR6 Research Grade Biosimilar (A324000) to identify and quantify DR6-expressing subpopulations within heterogeneous immune cell samples, particularly focusing on monocytes, resting CD4+ T cells, and pro-, pre-, and naïve B cells where DR6 expression has been documented . For intracellular signaling analysis, phosphoflow cytometry combines surface staining for DR6 with intracellular staining for phosphorylated signaling proteins (such as NF-κB pathway components) following DR6 stimulation or blockade, providing single-cell resolution of signaling events within specific immune cell subsets . Researchers investigating transcriptional responses should implement RNA-sequencing or qRT-PCR arrays following treatment with agonistic or antagonistic DR6 antibodies to identify downstream gene expression changes, with particular attention to cytokine production (IL4, IL5, IL10, IL13, and IFNG) which DR6 is known to negatively regulate in Th2 cells . Functional consequences of DR6 signaling can be assessed through ex vivo stimulation assays where isolated immune cell populations are treated with DR6 antibodies (either blocking or agonistic) followed by analysis of proliferation rates, apoptosis levels, and cytokine production profiles, with comparison to findings from DR6 knockout models which exhibit exaggerated Th2 and B cell responsiveness coupled with reduced Th1 cell responsiveness . For in vivo relevance, adoptive transfer experiments can be performed where immune cells treated with DR6 antibodies are transferred into recipient animals subjected to inflammatory challenges, such as those that induce airway inflammation or experimental autoimmune encephalitis, conditions for which DR6 knockout mice show altered susceptibility .

What considerations are important when designing experiments to evaluate the therapeutic potential of DR6-targeting antibodies?

When designing experiments to evaluate the therapeutic potential of DR6-targeting antibodies, researchers must first establish appropriate disease models that accurately reflect the pathophysiological role of DR6, such as neurodegeneration models for studying axonal pruning effects or autoimmune models that capitalize on findings that DR6 knockout mice exhibit resistance to experimental autoimmune encephalitis . The selection of appropriate antibody formats is critical, with therapeutic applications requiring antibodies like the low endotoxin, azide-free preparations (A324000) that minimize off-target effects, while considering whether antagonistic (blocking) or agonistic activity is desired based on the disease context and DR6's dual roles in apoptosis promotion and immune regulation . Dose-response relationships must be rigorously established through carefully designed dose-escalation studies, evaluating both efficacy parameters (such as neuroprotection measures or immune function readouts) and potential toxicity, with special attention to immunogenicity assessment when using antibodies across species . Pharmacokinetic and biodistribution studies are essential to determine antibody half-life, tissue penetration (particularly challenging for the blood-brain barrier in neurological applications), and optimal dosing intervals, potentially requiring radiolabeled or fluorescently tagged DR6 antibodies to track distribution in vivo . Additionally, combination treatment paradigms should be explored to determine whether DR6-targeting antibodies synergize with existing therapeutic approaches, such as combining with amyloid-targeting strategies in neurodegeneration models or with conventional immunosuppressants in autoimmune conditions, with careful attention to potential antagonistic interactions or enhanced toxicity profiles .

What are the common issues researchers encounter when working with DR6 antibodies and how can they be addressed?

Researchers working with DR6 antibodies frequently encounter specificity challenges due to DR6's extensive post-translational modifications, particularly its heavy glycosylation which can mask epitopes or create non-specific binding sites, necessitating verification through multiple detection methods and comparison of results using antibodies targeting different epitopes within the DR6 protein . Background signal problems in immunohistochemistry and immunofluorescence applications often occur due to the widespread expression of DR6 in various tissues, requiring careful titration of antibody concentrations, extended blocking steps with bovine serum albumin or normal serum (5-10%), and inclusion of thorough washing steps using PBS with 0.1-0.3% Tween-20 to remove unbound antibody . Reproducibility issues between experiments may stem from lot-to-lot variations, particularly with polyclonal antibodies, which can be mitigated by using monoclonal antibodies like the Luke-1 clone or recombinant antibodies that offer more consistent performance, along with implementing standardized protocols with precisely defined conditions for each experimental step . Sensitivity limitations may arise when attempting to detect low levels of DR6 expression in certain cell types or under specific conditions, which can be addressed through signal amplification methods such as tyramide signal amplification for immunohistochemistry or using more sensitive detection systems such as chemiluminescent substrates with extended exposure times for Western blots . Additionally, researchers should be vigilant about antibody storage conditions, as repeated freeze-thaw cycles can significantly impact antibody performance; aliquoting stock solutions and storing according to manufacturer recommendations (typically -20°C for long-term storage with 50% glycerol to prevent freezing damage) will help maintain consistent antibody activity throughout a research project .

How can researchers validate the specificity of DR6 antibodies in their experimental systems?

Comprehensive validation of DR6 antibody specificity requires multiple complementary approaches, beginning with genetic controls where researchers compare staining patterns between wild-type samples and those from DR6 knockout models or cells with CRISPR/Cas9-mediated DR6 gene deletion, which provides the most definitive evidence of antibody specificity . Pre-absorption tests offer another validation method, where the DR6 antibody is pre-incubated with excess purified DR6 protein or the immunizing peptide before application to samples, with the expectation that specific binding sites will be occupied during pre-incubation, resulting in diminished or absent signal in subsequent detection steps . Orthogonal method comparison involves validating protein expression using independent techniques such as correlating immunohistochemistry results with in situ hybridization data or mass spectrometry findings to confirm that protein detection aligns with mRNA expression patterns and proteomic data . Multi-antibody concordance testing, where researchers compare staining or detection patterns using multiple DR6 antibodies targeting different epitopes (such as comparing results between A15665, A283887, and A49829 antibodies), provides strong evidence for specificity when consistent patterns are observed across different antibody clones . Additionally, researchers should perform comprehensive positive and negative control testing across a tissue panel, confirming that antibodies detect DR6 in tissues known to express the receptor (such as lymphoid tissues, neural tissues, or certain cancer cells) while showing minimal background in tissues with low or absent expression, with results compared to established literature on DR6 expression patterns .

What are the key considerations for storage and handling of DR6 antibodies to maintain optimal activity?

Maintaining optimal DR6 antibody activity requires adherence to recommended storage temperatures, with long-term storage typically at -20°C to -70°C and short-term storage (1 month or less) at 2-8°C under sterile conditions after reconstitution, while strictly avoiding repeated freeze-thaw cycles which can cause antibody degradation through protein denaturation and aggregation . The composition of storage buffer significantly impacts antibody stability, with manufacturers typically providing DR6 antibodies in optimized formulations such as PBS with 1% BSA, 0.02% Proclin300, and 50% glycerol, where the glycerol prevents freezing damage and the BSA serves as a carrier protein to prevent antibody adsorption to storage container surfaces . Proper aliquoting strategies are essential upon receipt of DR6 antibodies, with researchers advised to prepare single-use aliquots based on typical experiment needs (often 5-10 μL) in sterile microcentrifuge tubes to minimize freeze-thaw cycles and reduce the risk of contamination in the stock solution . When working with reconstituted lyophilized antibodies, sterile technique must be employed throughout handling procedures, and researchers should accurately document the reconstitution date, as most DR6 antibodies maintain guaranteed activity for 6-12 months when stored properly according to manufacturer guidelines . Additionally, researchers should be aware that small volumes of antibody solution may occasionally become entrapped in the seal of product vials during shipment and storage, necessitating brief centrifugation in a tabletop centrifuge to dislodge any liquid in the container's cap before opening, particularly important when working with expensive and limited-quantity antibodies like the DR6 monoclonal antibody (Luke-1) which costs $595 per 0.1 mg .

How are DR6 antibodies being utilized in cancer research, particularly in relation to prostate cancer?

DR6 antibodies are increasingly valuable tools in cancer research due to findings that DR6 is constitutively expressed on some prostate cancer cells and can be induced by TNF-alpha on others, providing opportunities to study its role in cancer cell survival and apoptosis mechanisms . Researchers are employing immunohistochemistry with antibodies like Anti-TNFRSF21 (A44995) to characterize DR6 expression patterns across cancer types and stages, correlating expression levels with clinical outcomes and response to treatments, thereby establishing DR6 as a potential prognostic biomarker in prostate and other cancers . Functional studies utilizing blocking antibodies target DR6-mediated apoptosis pathways to determine whether DR6 activation or inhibition affects cancer cell survival, with particular interest in whether DR6's role in BAX-mediated apoptosis and cytochrome c release can be leveraged to enhance sensitivity to conventional chemotherapeutic agents in resistant cancer cell lines . Flow cytometry applications using antibodies such as the Anti-DR6 Research Grade Biosimilar (A324000) enable researchers to identify and isolate DR6-expressing cancer cell subpopulations from heterogeneous tumor samples, facilitating detailed molecular characterization of these cells through downstream transcriptomic and proteomic analyses to uncover potential therapeutic vulnerabilities . Additionally, DR6 antibodies are being explored in therapeutic development pipelines as potential delivery vehicles for cytotoxic payloads specifically to DR6-expressing cancer cells, with modified versions designed to either block survival pathways or activate apoptotic mechanisms depending on the specific cancer context and DR6 signaling patterns determined through preliminary mechanistic studies .

What are the emerging applications of DR6 antibodies in studying neurodegenerative diseases beyond Alzheimer's?

DR6 antibodies are finding expanded applications in studying multiple neurodegenerative conditions beyond Alzheimer's disease, building on the established role of DR6 in binding APP fragments and mediating neuronal apoptosis. Researchers are utilizing immunohistochemistry and co-immunoprecipitation with DR6 antibodies to investigate potential interactions between DR6 and disease-specific proteins in conditions such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease, exploring whether DR6 represents a common pathway in neurodegeneration across multiple conditions . In demyelinating disorders such as multiple sclerosis, DR6 antibodies are being employed to study the receptor's negative regulation of oligodendrocyte survival, maturation, and myelination, with blocking antibodies tested for their potential to promote remyelination by neutralizing DR6's inhibitory effects on oligodendrocyte lineage cells . Functional studies utilizing antibodies like the Anti-DR6 Research Grade Biosimilar (A324000) in animal models and organoid cultures of various neurodegenerative diseases are investigating whether DR6 blockade confers neuroprotection across multiple conditions, potentially identifying DR6 as a common therapeutic target regardless of the specific disease etiology . Time-course analyses employing immunofluorescence with DR6 antibodies are helping researchers determine the temporal relationship between DR6 activation and disease progression in various models, establishing whether DR6 signaling represents an early driver of pathology or a downstream consequence, which has significant implications for the timing of potential therapeutic interventions . Additionally, studies comparing the binding of DR6 antibodies in brain tissues from patients with different neurodegenerative conditions versus age-matched controls are revealing disease-specific patterns of DR6 expression and localization, potentially identifying novel diagnostic biomarkers or disease subtypes with distinct underlying mechanisms .

How can researchers effectively employ DR6 antibodies in the development of immunomodulatory therapies?

Researchers developing immunomodulatory therapies can leverage DR6 antibodies to capitalize on findings that DR6 knockout mice exhibit altered immune responses, including resistance to experimental autoimmune encephalitis but increased susceptibility to severe graft versus host disease, indicating complex and context-dependent roles in immune regulation. Initial therapeutic development requires comprehensive immune cell phenotyping using flow cytometry with antibodies like the Anti-DR6 Research Grade Biosimilar (A324000) to map DR6 expression across immune cell subsets in both healthy individuals and patients with specific autoimmune conditions, identifying potential target populations for therapeutic intervention . Ex vivo functional screening assays employing both antagonistic and agonistic DR6 antibodies can help determine whether DR6 blockade or activation would be beneficial in specific disease contexts, measuring outcomes such as cytokine production, proliferation rates, and cell fate decisions, with particular attention to effects on Th1/Th2 balance given DR6's established role in regulating these T cell subsets . For in vivo proof-of-concept studies, researchers can administer DR6 antibodies in relevant disease models such as experimental autoimmune encephalitis, collagen-induced arthritis, or allergen-induced airway inflammation, assessing both clinical outcomes and underlying immunological changes to establish therapeutic potential and mechanism of action . Antibody engineering approaches can enhance therapeutic profiles by creating modified DR6 antibodies with optimized properties such as altered Fc regions to engage or avoid specific effector functions, extended half-life variants for reduced dosing frequency, or bispecific formats that simultaneously target DR6 and other immunoregulatory molecules for synergistic effects . Additionally, researchers must implement comprehensive safety assessment protocols that monitor for unintended consequences of DR6 modulation, such as increased infection susceptibility, altered responses to vaccination, or unexpected effects on neuronal tissues, given DR6's dual roles in immune and nervous systems .